Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
Introduction; Chapitre 1: Le diagnostic; Chapitre 2: Le traitement; Chapitre 3: Les considérations financières; Chapitre 4: L'après-traitement; Chapitre 5: L'hérédité et les tests génétiques; Chapitre 6: Les récidives et les métastases; Chapitre 7: Les considérations juridiques; Chapitre 8: La prog…
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
Based on presentations from the American Society of Hematology 49th Annual Meeding and Exposition, December 8-11, 2007, Atlanta, Georgia
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.3 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.2 BC Cancer Agency VAN Library | Available |
Part I (12:19); Part II Body Scan (8:54)
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available |
The series is primarily intended to document the disease classifications used in the Population Health Impact of Disease in Canada (PHI) research program and help researchers to understand how the PHI estimates were calculated. It is also of interest to health professionals, advocacy groups, and in…
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available | ||
c.2 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.3 BC Cancer Agency VIC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
This publication represents the views and expert; opinions of an IARC Working Group on the; Evaluation of Carcinogenic Risks to Humans which met in Lyon (France) June 3 -10, 2014.
c.1 BC Cancer Agency VAN Library REF Statistics | Available |